Multibagger Selection: Perplexity's picks
Perplexity picked PGY, AEHR, MAZE, AAPG, RGTI with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Perplexity |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | PGY | — | 62% | — | — |
| 2 | AEHR | — | 55% | — | — |
| 3 | MAZE | — | 50% | — | — |
| 4 | AAPG | — | 48% | — | — |
| 5 | RGTI | — | 35% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +0.25% | +0.30% | 1.06x | 0 |
The model's market view
Small and mid-cap multibagger candidates face a selective environment: AI infrastructure, fintech operating leverage, and late-stage biotech catalysts are attracting capital, while valuations for quantum and AI-software names already embed substantial execution risk. The strongest asymmetric setups combine a verifiable near-term catalyst with revenue acceleration, improving profitability or cash flow, and sufficient liquidity to survive a full year without emergency dilution.
Why each pick
PGY
Pagaya combines scaled revenue growth with a demonstrated profitability and free-cash-flow inflection. Q2 FY2026 network volume rose 33% year over year to $3.5 billion and revenue rose 19% to $387 million, while the company raised FY2026 GAAP net-income guidance to $155-$180 million. At roughly $1.5 billion market capitalization against trailing free cash flow near $252 million, the equity retains meaningful upside capacity if volume growth and funding economics normalize. The thesis is an operating-leverage story rather than a pure valuation-discount story.
AEHR
Aehr is undergoing a sharp commercial inflection from automotive semiconductor test into AI-processor wafer-level burn-in and silicon photonics. It reported a record $60.7 million bookings quarter, approximately $100.6 million effective backlog, and FY2027 revenue guidance of $130-$150 million versus $50.0 million in FY2026. The stock has already re-rated sharply, so the investment case depends on backlog conversion and follow-on AI orders rather than a cheap starting valuation.
MAZE
Maze Therapeutics offers a binary but well-capitalized late-clinical catalyst path in APOL1-mediated kidney disease. Positive Phase 2 topline data for MZE829 were reported in March 2026, and the company raised about $150 million gross proceeds in a private placement to advance MZE829 and initiate Phase 2 trials for MZE782. The equity has strong analyst coverage and recent relative strength, but a 3x outcome is fundamentally dependent on clinical and regulatory success rather than operating fundamentals.
AAPG
Ascentage is a commercial-stage oncology company with accelerating product revenue, very high gross margins, and late-stage regulatory catalysts. First-half 2026 revenue rose 29.3% year over year to $44.5 million, trailing revenue rose about 64.5%, and the company reports approximately 94% gross margin. With about $279 million in cash and a stated runway through 2027, the main asymmetry comes from 2027 Phase 3 readouts for lisaftoclax in myelodysplastic syndromes and chronic myeloid leukemia.
RGTI
Rigetti is a high-risk quantum-computing option on superconducting-qubit progress, government and enterprise contracts, and eventual error-corrected quantum advantage. It meets the size, liquidity, and catalyst requirements, but its FY2025 revenue of only $7.1 million against an approximately $3.9 billion market capitalization means the valuation is almost entirely narrative- and technology-driven. It is included as the fifth-best candidate because quantum computing has genuine potential for rapid re-rating on verifiable technical or contract milestones, not because current financials support the price.
Other models on the same run
| Model | Picks |
|---|---|
| Muse Spark 1.1 | LUNR, ACHR, VERA, ENVX, SMR |
| Gemini 3 Pro | LUNR, RDW, SOUN, ACMR, RGTI |
| Claude Opus 5.5 | RCAT, LPTH, ONDS, AEHR, CAPR |
| DeepSeek | INOD, RZLV, FEIM, PVLA, AGIO |
| Grok 4.5 | INOD, NRIX, PVLA, CALX, FEIM |
| GPT-6 | BKSY, AMPX, RCAT, RDW, EOSE |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.